Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study evaluated the agreement between clinician and patient assessments of eyebrow and eyelash hair loss severity in adults with severe alopecia areata, using data from two phase 3 studies over 52 weeks.

The measures for eyebrow and eyelash hair loss in severe Alopecia Areata are reliable and useful for clinical trials.

Eyebrow and eyelash hair loss in alopecia areata worsens quality of life.

In this study, a strong positive correlation was found between clinician-reported and patient-reported measures for assessing eyebrow and eyelash hair loss in patients with severe alopecia areata, indicating high agreement during treatment with baricitinib over 52 weeks.

This study aimed to describe the distribution of eyebrow and eyelash hair loss in patients with varying severities of scalp hair loss from alopecia areata but does not report results.

Malnutrition can cause unusual eyelash growth and hair loss.

In this study, patients with severe alopecia areata treated with baricitinib over 152 weeks experienced sustained patient-reported improvements in scalp, eyebrow, and eyelash hair regrowth, with higher responders observed in the 4mg dose group compared to the 2mg group.

In this analysis of two trials, baricitinib showed eyebrow and eyelash regrowth in severe alopecia areata patients with greater than 20% scalp hair loss at Week 36, compared to placebo.

In this study, patients with alopecia areata who didn't initially respond to ritlecitinib at Week 24 showed improved response rates by Week 48, with up to 34% achieving better hair regrowth outcomes.

This study reported that most patients with alopecia areata who responded to ritlecitinib treatment by achieving a SALT score ≤20, SALT score ≤10, or improvements in eyebrow and eyelash assessments at Week 24 maintained their responses through Week 48.

This study found that baricitinib was effective in regrowing eyebrow and eyelash hair in patients with severe alopecia areata, with similar improvements observed in both clinician-reported and patient-reported measures.

This study found that some patients with alopecia areata who did not respond to ritlecitinib treatment by Week 24 achieved a positive response with continued therapy by Week 48, with tolerable side effects.

This article examines the morphological and physiological characteristics of eyelash follicles and offers clinical management suggestions for conditions like eyelash loss and trichomegaly, but presents no new clinical results.

This study found that ritlecitinib, taken daily, led to scalp, eyebrow, and eyelash hair regrowth in patients aged 12 and older with severe and very severe alopecia areata over a 24-month period.

Ritlecitinib is effective and safe for treating alopecia areata, promoting significant hair regrowth.

This study found that among patients with eyelash alopecia areata, 40% experienced complete regrowth of lashes, with a mean time to regrowth of 28 months.

This study found that the Brigham Eyelash Tool for Alopecia (BELA) is a reliable measure for assessing eyelash loss in alopecia areata patients, demonstrating high inter- and intrarater reliability.

This report describes a rare case of acquired eyelash trichomegaly in a 16-year-old female with systemic lupus erythematosus, accompanied by diffuse hair loss and "lupus hairs" on the scalp.

In these randomized, placebo-controlled trials, patients with alopecia areata who received baricitinib showed significantly higher eyebrow and eyelash hair regrowth rates compared to placebo, with greater responses observed at the 4 mg dose and in those achieving overall scalp hair improvement by Week 52.

This article discusses the contributions of Dr. Shoji Okuda to the field of hair transplantation and reports no new research findings.

This review discusses the essential qualifications and considerations for safely performing hair transplantation, including training, facilities, and patient selection criteria, but reports no clinical results.

A woman kept her eyelashes during chemotherapy possibly because of her glaucoma eye drops.

FUE is a minimally invasive hair transplant method using various donor sites.

This protocol outlines a study aiming to develop a universal patient-reported outcome measure for various hair disorders through qualitative interviews, with no new clinical results reported yet.

The document concludes that specialized hair transplant techniques can be effective, with varying success rates depending on the donor area and patient factors.

This study found that persistent significant alopecia was a common side effect following FEC-docetaxel chemotherapy, with a 33.4% global incidence, highlighting the need for awareness and potential preventative measures like cooling caps during treatment.

This study found that latanoprost may be effective for treating eyelash alopecia areata, achieving cosmetically acceptable regrowth in 45% of patients.

This article discusses various periocular conditions like madarosis, milphosis, trichomegaly, and dermatochalasis, and highlights their potential link to underlying local and systemic diseases, but reports no new clinical findings.

This study found significant differences in hair diameter between males and females across different zones of the safe donor area, which may aid in selecting optimal donor regions for hair transplantation surgeries.

This review suggests that radiofrequency devices may be effective for both hair removal and growth, depending on the RF modality, but further research is needed to clarify their efficacy and mechanisms.